Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of Dersimelagon in EPP or XLP
NCT05005975Phase 3Active, not recruiting
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Aug 2021
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of dersimelagon in erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), sponsored by Mitsubishi Tanabe Pharma Corporation. Started Aug 2021; status: active, not recruiting.
02
Drugs
dersimelagon
03
Conditions
erythropoietic protoporphyria (EPP)X-linked protoporphyria (XLP)
Beyond the preview
Go deeper on NCT05005975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05005975.